Transcriptional inhibition by interleukin-6 of the class A macrophage scavenger receptor in macrophages derived from human peripheral monocytes and the THP-1 monocytic cell line.
Expression of the class A macrophage scavenger receptor (MSR) contributes to the uptake of modified low density lipoproteins (LDL) by macrophages and transformation of these cells into lipid-laden foam cells, which characterize atherosclerosis. Many environmental factors, in particular, proinflammatory cytokines and growth factors, can exert regulatory effects on MSR expression, whereas intracellular accumulation of cholesterol itself does not influence MSR levels to any considerable extent. In the present study, by using an in vitro model, we examined whether stimulation with interleukin-6 (IL-6), an immunoregulatory, multipotential cytokine, modulates the expression and activities of the MSR in macrophages. When treated with IL-6, macrophages derived from peripheral monocytes and phorbol 12-myristate 13-acetate (PMA)-differentiated THP-1 monocytic cells showed significantly reduced uptake and/or binding of the MSR ligand, acetylated LDL. This effect was paralleled by a reduction in the expression of MSR protein and mRNA. Analysis of MSR promoter activity in THP-1 cells transfected with an MSR promoter-reporter gene construct demonstrated decreased activity of the MSR promoter in IL-6-treated THP-1 macrophages. Electrophoretic mobility gel shift assay also showed a reduction in the binding of a transcription factor to the MSR promoter AP-1/ets elements in IL-6-treated cells. Thus, exposure to IL-6 may inhibit expression of the class A MSR in differentiated macrophages at transcriptional levels. This result suggests that this cytokine may modulate foam cell formation during atherogenesis.
Liao
H S
HS
Cardiovascular and Pulmonary Research Institute, Allegheny University of the Health Sciences, Pittsburgh, PA, USA.
Matsumoto
A
A
Itakura
H
H
Doi
T
T
Honda
M
M
Kodama
T
T
Geng
Y J
YJ
D002232:Carbocyanines / Q000378:metabolism / Q000493:pharmacokinetics; D015870:Gene Expression; D006801:Humans; D015850:Interleukin-6 / Q000494:pharmacology*; D007963:Leukocytes, Mononuclear / Q000166:cytology; D008077:Lipoproteins, LDL / Q000187:drug effects / Q000378:metabolism / Q000493:pharmacokinetics; D008264:Macrophages / Q000737:chemistry*; D011401:Promoter Regions, Genetic; D011971:Receptors, Immunologic / Q000097:blood* / Q000187:drug effects* / Q000235:genetics; D051116:Receptors, Scavenger; D051117:Scavenger Receptors, Class A; D014157:Transcription Factors / Q000494:pharmacology; D014407:Tumor Cells, Cultured
D002232:Carbocyanines; D015850:Interleukin-6; D008077:Lipoproteins, LDL; C495139:MSR1 protein, human; D011971:Receptors, Immunologic; D051116:Receptors, Scavenger; D051117:Scavenger Receptors, Class A; D014157:Transcription Factors; C032629:acetyl-LDL; C024286:3,3'-dioctadecylindocarbocyanine